High-Level Overview
Daymark Health is a Philadelphia-based cancer care company that builds a tech-enabled platform delivering personalized, hybrid virtual and in-home supportive care to cancer patients.[1][2][6] It serves cancer patients by partnering with health plans, oncologists, and primary care providers to address clinical, mental health, social, and symptom management needs through 24/7 navigation, support, and coordination—solving the fragmentation in oncology care outside clinic walls, where patients spend over 8,000 hours annually.[1][3][6] The company launched in April 2025 with an $11.5 million seed round and secured $20 million in Series A funding in September 2025, led by Healthier Capital with Blue Venture Fund, enabling scaling to thousands of patients and new partnerships, including with Blue Cross Blue Shield of Rhode Island.[1][2][3]
Origin Story
Daymark Health was co-founded by oncologist Dr. Justin Bekelman (CEO), who identified gaps in comprehensive cancer care amid advances in treatments but persistent system fragmentation.[1][2] The idea emerged to create a full-risk, value-based model integrating clinical, social, and mental health support virtually and in-home, launched in April 2025 with seed funding of $11.5 million led by Maverick Ventures and Yosemite, plus Oncology Ventures.[2][5] Early traction came from partnering with a major Northeast payer to serve over 2,500 patients, proving the model's viability in real-world oncology workflows.[2][5] The Series A in September 2025 accelerated growth, adding board members like Dr. Aman Mahajan from Healthier Capital.[1][3]
Core Differentiators
- Tech-Enabled Platform: First-of-its-kind system for personalized care navigation, 24/7 support via phone/text/video, symptom management, medication guidance, and social resource connections (e.g., transportation, housing), delivered virtually or in-home by nurse practitioners, nurses, and social workers.[1][3][6]
- Full-Risk, Value-Based Model: Partners directly with payers to align incentives, manage total care costs, improve outcomes, and reduce silos—wrapping around existing oncologist workflows without disruption.[1][2][3]
- Hybrid Delivery: Combines virtual access with in-home visits, preferred by patients amid rising hospital-at-home trends; about 30% of cancer patients use home health vs. 8% non-cancer.[2][6]
- Evidence-Based Scaling: Proven with early partnerships (e.g., BCBSRI), backed by investors like Healthier Capital (founded by ex-One Medical CEO) for tech-driven outcomes.[1][3]
(Note: DaymarkSI.com [4] refers to a separate healthcare IT firm focused on data centers/AI/cloud, unrelated to Daymark Health's oncology platform.[4])
Role in the Broader Tech Landscape
Daymark rides the oncology tipping point, where 2 million+ annual U.S. cases, specialty drug cost pressures, and payer demands for value-based care converge with patient preferences for home-based models post-earlier discharges.[1][2][3] Timing aligns with hospital-at-home growth and payer-provider alignment on integrated care, breaking silos to cut avoidable costs while boosting access/experience.[1][5] It influences the ecosystem by partnering with health plans (e.g., BCBS plans via Blue Venture Fund) and oncologists, scaling tech platforms that redefine supportive oncology amid fragmented systems—potentially setting standards as in-home cancer services rise.[2][3]
Quick Take & Future Outlook
Daymark is poised to expand partnerships with more payers, invest in platform tech, and reach thousands amid oncology's shift to scalable, patient-first models.[3][5] Trends like AI-enhanced care coordination, full-risk contracts, and home health demand (especially for advanced cancers) will propel growth, with influence evolving toward national standards in value-based oncology.[1][2] As a well-funded innovator connecting clinic gaps, Daymark exemplifies tech's role in humanizing cancer journeys at scale.